Search Results

You are looking at 61 - 70 of 930 items for :

  • "community" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

James McCanney, Katy Winckworth-Prejsnar, Alyssa A. Schatz, Elizabeth A. Nardi, Andrea J. Dwyer, Christopher Lieu, Yelak Biru, and Robert W. Carlson

Executive Summary Advances in early detection and improved treatment during the past 30 years has led to a new issue in the oncology landscape: the unmet needs of the cancer survivor community. As of January 2017, there were >16.8 million

Full access

Jimmie C. Holland, Barbara Andersen, William S. Breitbart, Bruce Compas, Moreen M. Dudley, Stewart Fleishman, Caryl D. Fulcher, Donna B. Greenberg, Carl B. Greiner, Rev. George F. Handzo, Laura Hoofring, Paul B. Jacobsen, Sara J. Knight, Kate Learson, Michael H. Levy, Matthew J. Loscalzo, Sharon Manne, Randi McAllister-Black, Michelle B. Riba, Kristin Roper, Alan D. Valentine, Lynne I. Wagner, and Michael A. Zevon

and lack of knowledge of community resources. The need is particularly acute in community oncology practices that have few to no psychosocial resources, and cancer care is often provided in short visits. 4 For many centuries, patients were not told

Full access

Stephen R. Grant, Benjamin D. Smith, Lauren E. Colbert, Qunyh-Nhu Nguyen, James B. Yu, Steven H. Lin, and Aileen B. Chen

). Results A total of 42,685 courses met the criteria for inclusion, of which 60.2% were compliant according to NQF 1822. Compliance by patient and tumor characteristics is shown in Table 1 . Compliance at academic facilities was higher than at community

Full access

Stephen R. Grant, Benjamin D. Smith, Lauren E. Colbert, Qunyh-Nhu Nguyen, James B. Yu, Steven H. Lin, and Aileen B. Chen

). Results A total of 42,685 courses met the criteria for inclusion, of which 60.2% were compliant according to NQF 1822. Compliance by patient and tumor characteristics is shown in Table 1 . Compliance at academic facilities was higher than at community

Full access

Robert A. Smith

specificity and sensitivity of screening mammography [see comments] . J Natl Cancer Inst 1996 ; 88 : 643 – 649 . 53 Linver MN Paster SB Rosenberg RD . Improvement in mammography interpretation skills in a community radiology practice after

Full access

Razelle Kurzrock, A. Dimitrios Colevas, Anthony Olszanski, Wallace Akerley, Carlos L. Arteaga, William E. Carson III, Jeffrey W. Clark, John F. DiPersio, David S. Ettinger, Robert J. Morgan Jr, Lee S. Schwartzberg, Alan P. Venook, Christopher D. Gocke, Jonathan Tait, and F. Marc Stewart

the basis of disease, NCCN believes it is important to understand how such testing is being performed and used at NCCN Member Institutions and their community affiliates. In order to do so, the NCCN Oncology Research Program's (ORP) Investigator

Full access

Betsy Rolland and Jordan Eschler

increasing survivorship, NCI-designated Comprehensive Cancer Centers (CCCs) will be called on to take the lead for community providers and to act as sources of information for survivors, their caregivers, and clinicians as they navigate the next phase of care

Full access

Elizabeth A. Rohan, Beth Slotman, Amy DeGroff, Kerry Grace Morrissey, Jennifer Murillo, and Paul Schroy

increasing patient completion of cancer screening and reducing disparities among the medically underserved. 9 – 17 Generally, patient navigators (herein referred to as “navigators”) are either nonclinical members of the community or healthcare professionals

Full access

Thomas A. D’Amico, Lindsey A.M. Bandini, Alan Balch, Al B. Benson III, Stephen B. Edge, C. Lyn Fitzgerald, Robert J. Green, Wui-Jin Koh, Michael Kolodziej, Shaji Kumar, Neal J. Meropol, James L. Mohler, David Pfister, Ronald S. Walters, and Robert W. Carlson

patient advocacy, community oncology, and health information technology representatives, to review the existing quality landscape and identify contemporary, relevant cancer quality and outcomes measures by both reevaluating current validated measures and

Full access

Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack

within the urologic community that the 9% increase in disease-specific survival is of small magnitude. 24 Adjuvant Chemotherapy The NCCN Guidelines confer a category 2B recommendation (lower-level of evidence and consensus) for use of adjuvant